"We are not happy with your apology," Supreme Court to Ramdev on Patanjali misleading ads

DN Bureau

A bench of Justices Hima Kohli and Ahsanuddin Amanullah also refused to accept an apology tendered by Patanjali last month. Read further on Dynamite News:

Supreme Court
Supreme Court


New Delhi: The Supreme Court today denounced Ramdev and Balakrishna, co-founder and Managing Director of Patanjali Ayurveda respectively for their "absolute defiance" in not filing proper affidavits over the company's misleading advertisements.

"Not just the Supreme Court, every order passed by the courts across this country has to be respected. This is absolute defiance," the top court said.

The Apex Court observed that advertisements issued by Patanjali are in the "teeth of law" of the land. "Be ready for action," the Supreme Court warned Ramdev.

A bench of Justices Hima Kohli and Ahsanuddin Amanullah also refused to accept an apology tendered by Patanjali last month after the top court rap during the earlier hearing. "We are not happy with your apology," Justice Kohli said.

"You should have made sure that the solemn undertaking should have been in letter and spirit. We can also say that we are sorry for not accepting it. Your apology is not persuading this court. It is more of a lip service," the Supreme Court said.

After which, Ramdev's lawyer said both Ramdev and Balakrishna are ready to personally apologise in the court. "We want to apologise and are ready for whatever the court says," Senior advocate Balbir Singh told the court with folded hands.

The bench granted last opportunity to Ramdev and Balkrishna to file their affidavits in the matter in one week.

The Supreme Court also pulled up the Centre for not taking action and said they were sitting with their eyes shut. "We are wondering why the government chose to keep their eyes shut ," the bench had said.

The Supreme Court also asked Ramdev and Balkrishna to be present in the court on April 10 - the next date of hearing in the case.

On February 27, the top court had directed the company "to stop all electronic and print advertisements of its medicines giving misleading" information with immediate effect. (with Agency inputs)
 










Related Stories